Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic Syndromes: A Randomized Trial
The DOI matches its Crossref record; 34 of the 38 references it cites were found in a registry or an index.
Abstract
Background: Iron chelation therapy (ICT) in patients with lower-risk myelodysplastic syndromes (MDS) has not been evaluated in randomized studies. Objective: To evaluate event-free survival (EFS) and safety of ICT in iron-overloaded patients with low- or intermediate-1-risk MDS. Design: Multicenter, randomized, double-blind, placebo-controlled trial (TELESTO). (ClinicalTrials.gov: NCT00940602). Setting: 60 centers in 16 countries. Participants: 225 patients with serum ferritin levels greater than 2247 pmol/L; prior receipt of 15 to 75 packed red blood cell units; and no severe cardiac, liver, or renal abnormalities. Intervention: Deferasirox dispersible tablets (10 to 40 mg/kg per day) (n = 149) or matching placebo (n = 76). Measurements: The primary end point was EFS, defined as time from date of randomization to first documented nonfatal event (related to cardiac or liver dysfunction and transformation to acute myeloid leukemia) or death, whichever occurred first. Results: Median time on treatment was 1.6 years (interquartile range [IQR], 0.5 to 3.1 years) in the deferasirox group and 1.0 year (IQR, 0.6 to 2.0 years) in the placebo group. Median EFS was prolonged by approximately 1 year with deferasirox versus placebo (3.9 years [95% CI, 3.2 to 4.3 years] vs. 3.0 years [CI, 2.2 to 3.7 years], respectively; hazard ratio, 0.64 [CI, 0.42 to 0.96]). Adverse events occurred in 97.3% of deferasirox recipients and 90.8% of placebo recipients. Exposure-adjusted incidence rates of adverse events (≥15 events per 100 patient treatment-years) in deferasirox versus placebo recipients, respectively, were 24.7 versus 23.9 for diarrhea, 21.8 versus 18.7 for pyrexia, 16.7 versus 22.7 for upper respiratory tract infection, and 15.9 versus 0.9 for increased serum creatinine concentration. Limitations: The protocol was amended from a phase 3 to a phase 2 study, with a reduced target sample size from 630 to 210 participants. There was differential follow-up between treatment groups. Conclusion: The findings support ICT in iron-overloaded patients with low- to intermediate-1-risk MDS, with longer EFS compared with placebo and a clinically manageable safety profile. Therefore, ICT may be considered in these patients. Primary Funding Source: Novartis Pharma AG.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, a randomized study and meta‐analysis clarified that patients who were assigned to an ICT group showed longer survival, with low risk of progression to leukemia, compared with a non‐ICT group.42, 43”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [42]
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citationCheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Malcovati, L., Porta, M. G. D., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.7038 · Cited by 865
Tefferi, A., & Vardiman, J. W. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902908 · Cited by 670
Clinical Consequences of Acquired Transfusional Iron Overload in Adults
Schafer, A. I., Cheron, R. G., Dluhy, R., Cooper, B., Gleason, R. E., Soeldner, J. S., & Bunn, H. F. (1981) · New England Journal of Medicine · doi:10.1056/nejm198102053040603 · Cited by 295
Goldberg, S. L., Chen, E., Corral, M., Guo, A., Mody-Patel, N., Pecora, A. L., & Laouri, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2395 · Cited by 289
Malcovati, L., Della Porta, M. G., Strupp, C., Ambaglio, I., Kuendgen, A., Nachtkamp, K., Travaglino, E., Invernizzi, R., Pascutto, C., Lazzarino, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.044602 · Cited by 282
Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management
Montalban‐Bravo, G., & Garcia‐Manero, G. (2018) · American Journal of Hematology · doi:10.1002/ajh.24930 · Cited by 211
Self-citationRose, C., Brechignac, S., Vassilief, D., Pascal, L., Stamatoullas, A., Guerci, A., Larbaa, D., Dreyfus, F., Beyne-Rauzy, O., Chaury, M. P., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2009.12.004 · Cited by 195
Gattermann, N., Finelli, C., Porta, M. D., Fenaux, P., Ganser, A., Guerci-Bresler, A., Schmid, M., Taylor, K., Vassilieff, D., Habr, D., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.03.009 · Cited by 173
Research works printed but not linked: 1
- Germing U, 2004, Haematologica, 89, 905
Cited by
Reactive Oxygen Species in Cancer: Current Findings and Future Directions
Nakamura, H., & Takada, K. (2021) · Cancer Science · doi:10.1111/cas.15068 · Cited by 1,027
Cazzola, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1904794 · Cited by 491
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
Garcia‐Manero, G. (2023) · American Journal of Hematology · doi:10.1002/ajh.26984 · Cited by 216
Self-citationMyelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Garcia‐Manero, G., Chien, K. S., & Montalban‐Bravo, G. (2020) · American Journal of Hematology · doi:10.1002/ajh.25950 · Cited by 187
Self-citationFenaux, P., Haase, D., Santini, V., Sanz, G. F., Platzbecker, U., & Mey, U. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.002 · Cited by 163
Metadata
- Authors
- Angelucci, E., Li, J., Greenberg, P., Wu, D., Hou, M., Montaňo Figueroa, E. H., Rodriguez, M. G., Dong, X., Ghosh, J., Izquierdo, M., Garcia-Manero, G., & on behalf of the TELESTO Study Investigators*
- Affiliations
- Ospedale Policlinico San Martino (IT)
- Shanghai Jiao Tong University (CN)
- Stanford Medicine (US)
- First Affiliated Hospital of Soochow University (CN)
- Shandong University (CN)
- Department of Hematology, Hospital General de México, Mexico City, Mexico (E.H.M.)
- Mexican Social Security Institute (MX)
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (X.D., J.G.)
- Novartis (Switzerland) (CH)
- MD Anderson Cancer Center, University of Texas, Houston, Texas (G.G.)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2020-04-21
- Volume
- 172
- Issue
- 8
- Pages
- 513-522
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W3012730855
- Cited by
- 120
- References
- 38
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 14 · 2023: 20 · 2022: 25 · 2021: 24 · 2020: 12
- FWCI
- 12.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- iron chelation therapy, deferasirox, myelodysplastic syndrome, iron overload, transfusion dependence, event-free survival, adverse events, cardiac dysfunction, liver dysfunction, acute myeloid leukemia transformation, serum ferritin, red blood cell transfusion, fever
- MeSH terms
- Deferasirox, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Blood Transfusion, Cause of Death, Double-Blind Method, Female, Ferritins, Humans, Iron Chelating Agents, Male, Middle Aged, Myelodysplastic Syndromes, Iron Overload, Young Adult, Patient Acuity, Transfusion Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.